FDA Approves Gazyva for Rare Kidney Disease

The U.S. Food and Drug Administration (FDA) has approved obinutuzumab (Gazyva) for treating primary membranous nephropathy (PMN) in adults at risk of disease progression. This marks the first specific drug approval for this rare kidney disease, which causes proteinuria. Gazyva, a type II anti-CD20 monoclonal antibody, previously approved for certain cancers and lupus nephritis, received Breakthrough Therapy, Orphan Drug, and Priority Review designations, highlighting its significance for patients with PMN.